Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Current Assets (2021 - 2025)

Senti Biosciences has reported Current Assets over the past 5 years, most recently at $23.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 60.53% year-over-year to $23.3 million; the TTM value through Dec 2025 reached $23.3 million, down 60.53%, while the annual FY2025 figure was $23.3 million, 60.53% down from the prior year.
  • Current Assets for Q4 2025 was $23.3 million at Senti Biosciences, up from $18.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $143.9 million in Q2 2022 and troughed at $827152.0 in Q1 2022.
  • A 5-year average of $53.7 million and a median of $55.7 million in 2024 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: skyrocketed 9633.52% in 2023 and later plummeted 78.0% in 2024.
  • Year by year, Current Assets stood at $60.2 million in 2021, then soared by 70.42% to $102.6 million in 2022, then tumbled by 30.59% to $71.2 million in 2023, then dropped by 17.19% to $59.0 million in 2024, then crashed by 60.53% to $23.3 million in 2025.
  • Business Quant data shows Current Assets for SNTI at $23.3 million in Q4 2025, $18.2 million in Q3 2025, and $32.5 million in Q2 2025.